Analytical Data
-
Gene name
GPR52
- Application
-
Alternative Names
GPR52；G-Protein coupled receptor 52
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y2T5
-
Expression Region
1-361aa
-
AA Sequence
MNESRWTEWRILNMSSGIVNVSERHSCPLGFGHYSVVDVCIFETVVIVLLTFLIIAGNLTVIFVFHCAPLLHHYTTSYFIQTMAYADLFVGVSCLVPTLSLLHYSTGVHESLTCQVFGYIISVLKSVSMACLACISVDRYLAITKPLSYNQLVTPCRLRICIILIWIYSCLIFLPSFFGWGKPGYHGDIFEWCATSWLTSAYFTGFIVCLLYAPAAFVVCFTYFHIFKICRQHTKEINDRRARFPSHEVDSSRETGHSPDRRYAMVLFRITSVFYMLWLPYIIYFLLESSRVLDNPTLSFLTTWLAISNSFCNCVIYSLSNSVFRLGLRRLSETMCTSCMCVKDQEAQEPKPRKRANSCSI
-
Molecular Weight
41.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPR52, a member of the G protein-coupled receptor (GPCR) family, has garnered significant attention in recent years due to its potential role in various neurological disorders and its unique expression profile in the brain. Initially identified through genomic studies, GPR52 is characterized by its atypical structure and distinct signaling pathways, which set it apart from other GPCRs. Research indicates that GPR52 may influence dopaminergic signaling, making it a candidate for drug development targeting conditions like schizophrenia and Parkinson’s disease. Moreover, the receptor's involvement in modulating neurotransmitter release and synaptic plasticity highlights its potential as a therapeutic target for neuropsychiatric conditions. However, the lack of direct pharmacological agents and the challenges associated with studying GPR52 have necessitated the development of recombinant proteins to facilitate functional analyses and screening for ligands. Recent advancements in protein expression techniques have enabled researchers to produce GPR52 in a heterologous system, allowing for detailed characterizations of its pharmacological properties and biological functions. This foundational work aims to provide insights into GPR52's role in the central nervous system and to explore its therapeutic potential, paving the way for novel treatments for complex neuropsychiatric disorders.
